TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients

Genes Chromosomes and Cancer

Volumn 16, Issue 3, 1996, Pages 170-179

  Berns, Els M J J ^a   Klijn, Jan G M ^a   Smid, Marcel ^a   Van Staveren, Iris L ^a   Look, Maxime P ^a   Van Putten, Wim L J ^a   Foekens, John A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE MYC; ONCOGENE NEU; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BASE SEQUENCE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, MYC; GENES, P53; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEQUENCE ANALYSIS;

EID: 0029908595     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W     Document Type: Article

References (50)

1. Anderson TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68:540-548.
2. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703.
3. Benchimol S, Lamb P, Crawford LV, Sheer D, Shows TB, Bruns GAP, Peacock J (1985) Transformation-associated p53 protein is encoded by a gene on chromosome 17. Somatic Cell Mol Genet 11:505-508.
4. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 10:1029-1034.
5. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H, Foekens JA (1992) c-Myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52:1107-1113.
6. Berns EMJJ, Foekens JA, van Staveren IL, van Putten WLJ, de Koning HYWCM, Portengen H, Klijn JGM (1995) Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11-18.
7. Borresen A-L, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S, Corneliss CJ, Hovig E, Devilee P (1995) TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosom Cancer 14:71-75.
8. Caleffi M, Teaque MW, Jensen RA, Vnencak CL, Dupont WD, Pari FF (1994) P53 gene mutations and steroid receptor status in breast cancer. Cancer 73:2147-2156.
9. Carbone D, Chiba I, Mitsudomi T (1991) Polymorphism at codon 213 within the p53 gene. Oncogene 6:1691.
10. Cariello NF, Cui L, Beroud C, Soussi T (1994) Database and software for the analysis of mutations in the human p53 gene. Cancer Res 54:4454-4460.
11. Cho Y, Gorina S, Jeffery PD, Pavletich NP (1994) Crystal structure of a TP53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 256:346-355.
12. Davidoff AM, Iglehart JD, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 88:3439-3442.
13. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
14. Elledge RM, Allred DG (1994) The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treatment 32:39-47.
15. EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16:1513-1515.
16. Eyfjord JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir H, Anamthawat-Jonsson K (1995) p53 Abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55:646-651.
17. Foekens JA, Portengen H, van Putten, Klijn JGM (1989) Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009.
18. Foekens JA, Portengen H, van Putten WLJ, Klijn JGM (1993) Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 11:899-908.
19. Friend S (1994) p53: A glimpse at the puppet behind the shadow play. Science 265:334-335.
20. Gasparini G, Weidner N, Bevilacqua (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral vessel invasion are relevant prognostic markers in node negative breast carcinoma. J Clin Oncol 12:454-466.
21. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
22. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097.
23. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
24. Harris AL (1992) p53 Expression in human breast cancer. Adv Cancer Res 59:69-88.
25. Hartmann A, Blaszyk H, Mc Govern RM, Schroeder JJ (1995) p53 Gene mutations inside and outside of exons 5-8: The patterns differ in breast and other cancers. Oncogene 10:681-688.
26. Hartwell L (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546.
27. Hollstein M, Siddransky D, Vogelstein B, Harris CC (1991) p53 Mutations in human cancers. Science 253:49-53.
28. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
29. Levine AJ, Momand J, Finlay, CA (1991)The p53 tumor suppressor gene. Nature 351:453-456.
30. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D (1993) The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 83:403-410.
31. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD (1992) Altered cell cycle arrest and gene amplification potential accompanying loss of wild type p53. Cell 70:923-935.
32. Lowe SW, Schmitt EM, Smith SW, Osborne B, Jacks T (1993) P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:837-849.
33. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 Status and the effect of cancer therapy in vivo. Science 266:807-810.
34. Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, Theillet C (1992) pS3 Mutations occur in aggressive breast cancer. Cancer Res 52:3918-3923.
35. Merlo GR, Bernardi A, Diella F, Venesio T, Cappa APM, Callahan R, Liscia D (1993) In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with high S-phase index. Int J Cancer 54:531-535.
36. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
37. Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266.
38. Oren M (1994) Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 5:221-227.
39. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T (1989a) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766-2770.
40. Orita M, Suzuki Y, Sekiya T, Hayashi K (1989b) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-879.
41. Prives C (1994) How loops, b sheets and a helices help us to understand p53. Cell 78:543-546.
42. Prosser J, Thomson AM, Cranston G, Evans HJ (1990) Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors. Oncogene 5:1573-1579.
43. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L (1995) p53 In node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13:821-830.
44. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S (1991) Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88:10657-10661.
45. Service R (1994) Slow DNA repair implicated in mutations found in tumors. Science 263:1374.
46. Smith ML, Chen IT, Zhan Q, Bae I, Chen C-Y, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ (1994) Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380.
47. Thor A, Moore DH, Edgarton SM, Kawasaki ES, Reihaus E, Lynch HT, Macus JN, Schwartz, L, Chen L-C, Mayall BH, Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855.
48. Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human p53: New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244.
49. Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578.
50. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 Is a universal inhibitor of cyclin kinases. Nature 366: 701-704.